Portola Pharmaceuticals

270 East Grand Avenue
South San Francisco
United States

Tel: 650-246-7000
Fax: 650-246-7376

Email: contact@portola.com

Show jobs for this employer

About Portola Pharmaceuticals

We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases.

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Founding date:  September 23, 2003

Executive Team

CEO:  Scott Garland  (effective 10/8/18)

CFO:  Mardi Dier

Executive VP, R&D: John Curnutte MD PhD

Executive VP, Chief Human Resources Officer:  Ernie Meyer

Executive VP, General Counsel: John Moriarty

Senior VP, Technical Operations: Glenn Brame

Senior VP, Chief Medical Officer: John H. (Jack) Lawrence MD

Please click here for Portola job opportunities.


Please click here for clinical trial information.


Tweets by Portola


224 articles with Portola Pharmaceuticals